Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.040
Filtrar
1.
Recurso de Internet en Portugués | LIS - Localizador de Información en Salud | ID: lis-LISBR1.1-46933

RESUMEN

Mais de 140 mil pessoas no mundo morreram em decorrência do sarampo em 2018, de acordo com novas estimativas da Organização Mundial da Saúde (OMS) e dos Centros para Controle e Prevenção de Doenças (CDC) dos Estados Unidos. Essas mortes ocorreram em um momento em que os casos de sarampo aumentaram globalmente, com surtos devastadores em todas as regiões.


Asunto(s)
Sarampión , Sarampión/mortalidad
2.
Epidemiol Infect ; 147: e319, 2019 12 11.
Artículo en Inglés | MEDLINE | ID: mdl-31822310

RESUMEN

A large-scale measles outbreak (11 495 reported cases, 60% aged ≥15 years) occurred in Georgia during 2013-2015. A nationwide, multistage, stratified cluster serosurvey for hepatitis B and C among persons aged ≥18 years conducted in Georgia in late 2015 provided an opportunity to assess measles and rubella (MR) susceptibility after the outbreak. Residual specimens from 3125 participants aged 18-50 years were tested for Immunoglobulin G antibodies against MR using ELISA. Nationwide, 6.3% (95% CI 4.9%-7.6%) of the surveyed population were seronegative for measles and 8.6% (95% CI 7.1%-10.1%) were seronegative for rubella. Measles susceptibility was highest among 18-24 year-olds (10.1%) and declined with age to 1.2% among 45-50 year-olds (P < 0.01). Susceptibility to rubella was highest among 25-29 year-olds (15.3%), followed by 18-24 year-olds (11.6%) and 30-34 year-olds (10.2%), and declined to <5% among persons aged ≥35 years (P < 0.001). The susceptibility profiles in the present serosurvey were consistent with the epidemiology of recent MR cases and the history of the immunization programme. Measles susceptibility levels >10% among 18-24 year-olds in Georgia revealed continued risk for outbreaks among young adults. High susceptibility to rubella among 18-34 year-olds indicates a continuing risk for congenital rubella cases.


Asunto(s)
Sarampión/epidemiología , Rubéola (Sarampión Alemán)/epidemiología , Adolescente , Adulto , Brotes de Enfermedades , Susceptibilidad a Enfermedades , Femenino , Georgia (República)/epidemiología , Humanos , Masculino , Sarampión/sangre , Sarampión/diagnóstico , Sarampión/prevención & control , Persona de Mediana Edad , Rubéola (Sarampión Alemán)/sangre , Rubéola (Sarampión Alemán)/diagnóstico , Rubéola (Sarampión Alemán)/prevención & control , Estudios Seroepidemiológicos , Adulto Joven
3.
Inquiry ; 56: 46958019894098, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31823676

RESUMEN

Since 2018 and currently in 2019, the United States and Canada experienced a rapidly spreading measles virus outbreak. The developing outbreak may be due to a lack of vaccination, an inadequate dosage of measles (MMR) vaccine, clusters of intentionally under-vaccinated children, imported measles from global travel, and from those who are immunocompromised or have other life-threatening diseases. The infection originated mainly from travelers who acquired measles abroad and has thus led to a major outbreak and health concern not only in the United States and Canada but also in other parts of the world. According to World Health Organization, from January 2019 through September 2019, 1234 cases of measles have been reported in the United States and 91 reported cases in Canada, while in 2018, 372 and 28 cases were reported in the United States and Canada, respectively. A potential driving factor to the increased cases maybe because fewer children have been vaccinated over the last number of years in both countries. This article is a narrative review of cases discussing the measles outbreak among partially vaccinated and unvaccinated children and adults in the United States and Canada in 2018 and 2019.

5.
Am J Infect Control ; 2019 Dec 12.
Artículo en Inglés | MEDLINE | ID: mdl-31839277

RESUMEN

BACKGROUND: Patients with measles can precipitate outbreaks in health care facilities where they seek care. Rural critical-access hospitals (CAHs) may be at higher risk of outbreaks given their size and potentially limited infection prevention resources. METHODS: We surveyed CAHs in Idaho to ascertain their levels of preparedness for managing measles cases. A 25-item questionnaire was sent to infection preventionists at all 27 Idaho CAHs. The questionnaire covered organizational structure, resources for managing measles cases, and hospital policies for ensuring immunity among health care workers. RESULTS: A total of 22 (82%) CAHs responded, reporting varying availability of facilities and resources for managing measles cases and disparate procedures for testing clinical samples and providing vaccines to nonimmune, exposed staff. DISCUSSION: With measles incidence on the rise in the United States, our survey found that most of the responding hospitals had the basic organizational structure for facility-wide prevention and management efforts in case a patient with suspected or confirmed measles presented to that facility. Most of the hospitals also had at least some available resources to manage measles cases, as well as policies for ensuring immunity to measles among at least some groups of health care workers. CONCLUSIONS: This study provides initial perspectives on measles preparedness among Idaho CAHs, despite limited generalizability. Future studies should explore whether self-reported preparedness measures reflect the ability of the CAHs to control measles spread when cases present for care.

6.
JAMA Pediatr ; : e194515, 2019 Dec 09.
Artículo en Inglés | MEDLINE | ID: mdl-31816033

RESUMEN

Importance: The US population is experiencing a resurgence of measles, with more than 1000 cases during the first 6 months of 2019. Imported measles cases among returning international travelers are the source of most US measles outbreaks, and these importations can be reduced with pretravel measles-mumps-rubella (MMR) vaccination of pediatric travelers. Although it is estimated that children account for less than 10% of US international travelers, pediatric travelers account for 47% of all known measles importations. Objective: To examine clinical practice regarding MMR vaccination of pediatric international travelers and to identify reasons for nonvaccination of pediatric travelers identified as MMR eligible. Design, Setting, and Participants: This cross-sectional study of pediatric travelers (ages ≥6 months and <18 years) attending pretravel consultation at 29 sites associated with Global TravEpiNet (GTEN), a Centers for Disease Control and Prevention-supported consortium of clinical sites that provide pretravel consultations, was performed from January 1, 2009, through December 31, 2018. Main Outcomes and Measures: Measles-mumps-rubella vaccination among MMR vaccination-eligible pediatric travelers. Results: Of 14 602 pretravel consultations for pediatric international travelers, 2864 travelers (19.6%; 1475 [51.5%] males; 1389 [48.5%] females) were eligible to receive pretravel MMR vaccination at the time of the consultation: 365 of 398 infants aged 6 to 12 months (91.7%), 2161 of 3623 preschool-aged travelers aged 1 to 6 years (59.6%), and 338 of 10 581 school-aged travelers aged 6 to 18 years (3.2%). Of 2864 total MMR vaccination-eligible travelers, 1182 (41.3%) received the MMR vaccine and 1682 (58.7%) did not. The MMR vaccination-eligible travelers who did not receive vaccine included 161 of 365 infants (44.1%), 1222 of 2161 preschool-aged travelers (56.5%), and 299 of 338 school-aged travelers (88.5%). We observed a diversity of clinical practice at different GTEN sites. In multivariable analysis, MMR vaccination-eligible pediatric travelers were less likely to be vaccinated at the pretravel consultation if they were school-aged (model 1: odds ratio [OR], 0.32 [95% CI, 0.24-0.42; P < .001]; model 2: OR, 0.26 [95% CI, 0.14-0.47; P < .001]) or evaluated at specific GTEN sites (South: OR, 0.06 [95% CI, 0.01-0.52; P < .001]; West: OR, 0.10 [95% CI, 0.02-0.47; P < .001]). The most common reasons for nonvaccination were clinician decision not to administer MMR vaccine (621 of 1682 travelers [36.9%]) and guardian refusal (612 [36.4%]). Conclusions and Relevance: Although most infant and preschool-aged travelers evaluated at GTEN sites were eligible for pretravel MMR vaccination, only 41.3% were vaccinated during pretravel consultation, mostly because of clinician decision or guardian refusal. Strategies may be needed to improve MMR vaccination among pediatric travelers and to reduce measles importations and outbreaks in the United States.

7.
Med Sci Monit ; 25: 9245-9254, 2019 Dec 04.
Artículo en Inglés | MEDLINE | ID: mdl-31800568

RESUMEN

BACKGROUND Measles morbidity and mortality were significantly reduced after the measles vaccine was introduced in China in 1965. However, measles outbreaks easily occur in densely populated areas, especially where there is no universal vaccination. The outbreak that occurred in Shenzhen, the Chinese city with the largest internal immigration, provides a lesson in measles virus mutation and measles prevention. The present study is a phylogenetic analysis of measles viruses and comparison of clinical signs between individuals with and without vaccination. MATERIAL AND METHODS We performed phylogenetic analysis of the nucleoprotein (N) genes of measles virus from 129 measles patients in Shenzhen from January 2015 to July 2019. Phylogenetic trees were constructed using the neighbor-joining method. RESULTS The phylogenetic analysis showed all viruses were classified into genotype H1. In addition, there is often a seasonal measles outbreak in July each year. The clinical data showed that patients who were unvaccinated were more likely to have coughing, chronic bronchitis, conjunctivitis, catarrh, Koplik spots, and diarrhea. Children of migrant workers and those living in mountainous and rural districts accounted for most measles cases. CONCLUSIONS Our results showed there was a seasonal measles outbreak in Shenzhen Children's Hospital. All the measles virus from 129 measles patients were H1 viruses. The clinical signs also showed a difference between unvaccinated and vaccinated patients. Moreover, most of the unvaccinated patients came from migrant worker families. We suggest there is a need for increased health promotion and vaccination programs for migrant workers and people living in remote villages.


Asunto(s)
Virus del Sarampión/genética , Sarampión/epidemiología , Niño , Preescolar , China/epidemiología , Brotes de Enfermedades , Femenino , Genotipo , Humanos , Inmunoglobulina M , Lactante , Recién Nacido , Masculino , Vacuna Antisarampión , Virus del Sarampión/patogenicidad , Nucleoproteínas/genética , Filogenia , Vacunación , Proteínas Virales/genética
9.
MMWR Morb Mortal Wkly Rep ; 68(48): 1105-1111, 2019 Dec 06.
Artículo en Inglés | MEDLINE | ID: mdl-31805033

RESUMEN

In 2010, the World Health Assembly (WHA) set the following three milestones for measles control to be achieved by 2015: 1) increase routine coverage with the first dose of measles-containing vaccine (MCV1) among children aged 1 year to ≥90% at the national level and to ≥80% in every district, 2) reduce global annual measles incidence to less than five cases per 1 million population, and 3) reduce global measles mortality by 95% from the 2000 estimate* (1). In 2012, WHA endorsed the Global Vaccine Action Plan,† with the objective of eliminating measles§ in five of the six World Health Organization (WHO) regions by 2020. This report updates a previous report (2) and describes progress toward WHA milestones and regional measles elimination during 2000-2018. During 2000-2018, estimated MCV1 coverage increased globally from 72% to 86%; annual reported measles incidence decreased 66%, from 145 to 49 cases per 1 million population; and annual estimated measles deaths decreased 73%, from 535,600 to 142,300. During 2000-2018, measles vaccination averted an estimated 23.2 million deaths. However, the number of measles cases in 2018 increased 167% globally compared with 2016, and estimated global measles mortality has increased since 2017. To continue progress toward the regional measles elimination targets, resource commitments are needed to strengthen routine immunization systems, close historical immunity gaps, and improve surveillance. To achieve measles elimination, all communities and countries need coordinated efforts aiming to reach ≥95% coverage with 2 doses of measles vaccine (3).


Asunto(s)
Erradicación de la Enfermedad , Salud Global/estadística & datos numéricos , Sarampión/prevención & control , Adolescente , Adulto , Niño , Preescolar , Humanos , Programas de Inmunización , Incidencia , Lactante , Sarampión/epidemiología , Sarampión/mortalidad , Vacuna Antisarampión/administración & dosificación , Adulto Joven
10.
MMWR Morb Mortal Wkly Rep ; 68(48): 1112-1116, 2019 Dec 06.
Artículo en Inglés | MEDLINE | ID: mdl-31805034

RESUMEN

In 2005, the World Health Organization (WHO) Western Pacific Region countries, including China, resolved to eliminate measles by 2012 or as soon as feasible thereafter (1). As of 2018, nine* of the 37 Western Pacific Region countries or areas† had eliminated§ measles. China's Measles Elimination Action Plan 2006-2012 included strengthening routine immunization; conducting measles risk assessments, followed by supplementary immunization activities (SIAs) with measles-containing vaccine (MCV) at national and subnational levels; strengthening surveillance and laboratory capacity; and investigating and responding to measles outbreaks. Most recently, progress toward measles elimination in China was described in a 2014 report documenting measles elimination efforts in China during 2008-2012 and a resurgence in 2013 (2). This report describes progress toward measles elimination in China during January 2013-June 2019.¶ Measles incidence per million persons decreased from 20.4 in 2013 to 2.8 in 2018; reported measles-related deaths decreased from 32 in 2015 to one in 2018 and no deaths in 2019 through June. Measles elimination in China can be achieved through strengthening the immunization program's existing strategy by ensuring sufficient vaccine supply; continuing to improve laboratory-supported surveillance, outbreak investigation and response; strengthening school entry vaccination record checks; vaccinating students who do not have documentation of receipt of 2 doses of measles-rubella vaccine; and vaccinating health care professionals and other adults at risk for measles.


Asunto(s)
Erradicación de la Enfermedad , Brotes de Enfermedades/prevención & control , Sarampión/prevención & control , Vigilancia de la Población , Adolescente , Niño , Preescolar , China/epidemiología , Brotes de Enfermedades/estadística & datos numéricos , Femenino , Humanos , Programas de Inmunización , Incidencia , Lactante , Masculino , Sarampión/epidemiología , Sarampión/mortalidad , Vacuna Antisarampión/administración & dosificación
11.
Hum Vaccin Immunother ; : 1-9, 2019 Dec 10.
Artículo en Inglés | MEDLINE | ID: mdl-31810408

RESUMEN

Simultaneous administration of different vaccines is a strategy to increase the possibility to receive vaccines at appropriate age, safely and effectively, reducing the number of sessions and allowing a more acceptable integration of new vaccines into National Immunization Programs (NIPs). Co-administration can be performed when there are specific indications in the Summary of Product Characteristics (SmPC) of the vaccines; but, in absence of these indications, the practice is possible if there are no specific contraindications nor scientific evidence to discourage simultaneous administration.The aim of this work is to review the safety and efficacy of co-administration of the tetravalent measles, mumps, rubella, and varicella (MMRV) and the meningococcal C (Men C) conjugate vaccines after 12 months of age.Several studies demonstrated that MMRV and Men C conjugate vaccines can be administered concomitantly without a negative impact on the safety and immunogenicity of either vaccines, inducing highly immunogenic responses.

12.
Vaccines (Basel) ; 7(4)2019 Nov 28.
Artículo en Inglés | MEDLINE | ID: mdl-31795157

RESUMEN

Despite efforts to improve surveillance and vaccination coverage, measles virus (MeV) continues to cause outbreaks also in high-income countries. As the reference laboratory of the Veneto Region, Italy, we analyzed changes in population immunity, described measles outbreaks, investigated MeV genetic diversity, and evaluated cross-protection of measles vaccination against MeV epidemic strains. Like most European areas, the Veneto Region has suboptimal measles vaccination coverage and is facing a growing public mistrust of vaccination. A progressive decline of measles vaccine uptake was observed during the last decade in the Veneto Region, leading to immunity gaps in children and young adults. Measles outbreaks were caused by the same MeV genotype B3, D4, and D8 strains that were circulating in other European countries. Eleven cases of measles were observed in immunized subjects. These cases were not associated with particular MeV genotypes nor with mutations in epitopes recognized by neutralizing antibodies. Accordingly, sera from fully vaccinated subjects cross-neutralized epidemic MeV strains, including the genotypes B3, D4, and D8, with the same high efficiency demonstrated against the vaccine strain. In fully vaccinated subjects, high MeV IgG antibody titers persisted up to 30 years following vaccination. These results support the use of the current measles-containing vaccines and strategies to strengthen vaccination.

13.
BMJ Case Rep ; 12(12)2019 Dec 02.
Artículo en Inglés | MEDLINE | ID: mdl-31796443

RESUMEN

A 40-year-old British man presented to the emergency department for the second time in 10 days following a 2-week holiday in Thailand with malaise, bilateral conjunctivitis and a morbilliform rash. He had previously seen his general practitioner and ophthalmology and was diagnosed with conjunctivitis. We confirmed measles following RNA detection on a mouth swab. Four days after admission he developed abdominal pain and a CT abdomen demonstrated acute appendicitis with large appendicoliths. A perforated appendix was identified intraoperatively. Measles RNA was detected in the resected appendix. Preoperatively he developed hypoxia with right upper lobe changes seen on a CT pulmonary angiogram. Bronchoalveolar lavage performed in theatre isolated measles RNA at high level, consistent with measles pneumonitis. He required ventilatory support in the intensive care unit and was also treated with intravenous antibiotics. He made a complete recovery.


Asunto(s)
Apendicitis/diagnóstico , Sarampión/diagnóstico , Neumonía Viral/etiología , Adulto , Apendicitis/microbiología , Apendicitis/cirugía , Apendicitis/virología , Trazado de Contacto/métodos , Diagnóstico Tardío , Humanos , Masculino , Sarampión/complicaciones , Sarampión/genética , Neumonía Viral/diagnóstico por imagen , Neumonía Viral/terapia , Respiración Artificial , Salmonella/aislamiento & purificación
14.
J Epidemiol Glob Health ; 9(4): 294-299, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31854172

RESUMEN

Measles is a highly transmissible viral infection that may lead to serious illness, lifelong complications, and death. As there is no animal reservoir for measles, measles resurgence is due to human movement of viremic persons. Therefore, some have blamed the enormous migration into Europe in the past 5 years for the measles resurgence in this region. We set out to determine the main driver for measles resurgence in Europe by assessing vaccine coverage rates and economic status in European countries, number of migrants, and travel volumes. Data on measles vaccine coverage rates with two vaccine doses of measles, mumps and rubella (MMR) [Measles Containing Vaccine (MCV)2] and total number of measles cases in 2017 for Europe, including Eastern European countries, were obtained, in addition to Gross Domestic Product (GDP), and number of migrants and tourist arrivals. The outcome measured, incidence of measles per 100,000, was log transformed and subsequently analyzed using multiple linear regression, along with predictor variables: number of international migrants, GDP per capita, tourist arrivals, and vaccine coverage. The final model was interpreted by exponentiating the regression coefficients. Incidence of measles was highest in Romania (46.1/100,000), followed by Ukraine (10.8/100,000) and Greece (8.7/100,000). MCV2 coverage in these countries is less than 84%, with lowest coverage rate (75%) reported in Romania. Only vaccine coverage appears to be the significant predictor in the model (p < 0.001) for incidence of measles even after adjusting for international migrants, international tourist arrivals, and GDP per capita. With one unit increase in vaccination coverage, the incidence of measles decreased by 18% [95% confidence interval (CI): 10-25]. Our results showed that number of migrants and international tourist arrivals into any of the European countries were not the drivers for increased measles cases. Countries with high vaccine coverage rates regardless of economic status did not experience a resurgence of measles, even if the number of migrants or incoming travellers was high. The statistically significant sole driver was vaccine coverage rates. These analyses reemphasize the importance of strategies to improve national measles vaccination to achieve coverage greater than 95%.

15.
Washington, D.C.; PAHO; 2019-12-13.
en Inglés, Español | PAHO-IRIS | ID: phr-51853

RESUMEN

Between 1 January and 12 December 2019, a total of 15,802 confirmed cases of measles, including 18 deaths, have been reported in 14 countries and territories of the Region of the Americas: Argentina (85 cases), the Bahamas (3 cases), Brazil (13,489 cases, including 15 deaths), Canada (113 cases), Chile (11 cases), Colombia (230 cases, including 1 death), Costa Rica (10 cases), Cuba (1 case), Curaçao (1 case), Mexico (20 cases), Peru (2 cases), the United States of America (1,276 cases), Uruguay (9 cases), and the Bolivarian Republic of Venezuela (552 cases, including 2 deaths). In 2018, the highest proportion of confirmed cases in the Region of the Americas was reported in Brazil (62%) and Venezuela (34%). In 2019, the majority of confirmed cases have been reported from Brazil (85%). Since the PAHO/WHO Epidemiological Update on Measles published on 1 November 2019, there has been a 37.6% increase in the total number of confirmed cases of measles reported, with 9 countries reporting additional confirmed cases: Argentina (47 cases), the Bahamas (1 case), Brazil (4,185 cases), Canada (1 case), Chile (1 case), Colombia (18 cases), Mexico (4 cases), the United States (26 cases), and Venezuela (32 cases).


Desde el 1 de enero al 12 de diciembre de 2019 se notificaron 15.802 casos confirmados de sarampión, incluidas 18 defunciones, en 14 países y territorios de la Región: Argentina (85 casos), Bahamas (3 casos), Brasil (13.489 casos, incluidas 15 defunciones), Canadá (113 casos), Chile (11 casos), Colombia (230 casos, incluida 1 defunción), Costa Rica (10 casos), Cuba (1 caso), Curazao (1 caso), los Estados Unidos de América (1.276 casos), México (20 casos), Perú (2 casos), Uruguay (9 casos) y la República Bolivariana de Venezuela (552 casos, incluidas 2 defunciones). En 2018, la mayor proporción de casos confirmados de la Región de las Américas se registró en Brasil (62%) y Venezuela (34%). En 2019, la mayoría de los casos confirmados proviene de Brasil (85%). Desde la Actualización Epidemiológica de sarampión publicada el 1 de noviembre de 2019, hubo un incremento de 37,6% en el total de casos confirmados, dado que 9 países han notificado casos confirmados adicionales: Argentina (47 casos), Bahamas (1 caso), Brasil (4.185 casos), Canadá (1 caso), Chile (1 caso), Colombia (18 casos), Estados Unidos de América (26 casos), México (4 casos) y Venezuela (32 casos).


Asunto(s)
Reglamento Sanitario Internacional , Urgencias Médicas , Sarampión , Reglamento Sanitario Internacional , Urgencias Médicas , Sarampión
17.
Rev. peru. med. exp. salud publica ; 36(4): 610-619, oct.-dic. 2019. tab, graf
Artículo en Español | LILACS-Express | ID: biblio-1058769

RESUMEN

RESUMEN Objetivos . Estimar la cobertura y determinar los factores asociados a la vacunación contra el sarampión en Perú. Materiales y métodos . Realizamos un estudio de fuente secundaria utilizando la Encuesta Demográfica y de Salud Familiar (ENDES) del 2017, la unidad informante fue una mujer en edad fértil de 15 a 49 años; la unidad de análisis fue un niño de 12 a 59 meses (para la primera dosis) o niño de 18 a 59 meses (para la dosis de refuerzo) y que contaba con datos de vacunación. Los datos de cobertura fueron obtenidos de la tarjeta de vacunación. Resultados . Según la tarjeta de vacunación, la cobertura para la primera dosis fue del 70,2% (IC95%: 68,8-71,6), para la dosis de refuerzo del 52,0% (IC95%: 50,5-53,6). Los niños de 24-35 meses tuvieron más probabilidades de ser vacunados para la primera dosis (OR: 1,59; IC95%: 1,28-1,97) y dosis de refuerzo (OR:2,04; IC95%: 1,62-2,56) comparado con los niños de 12-23 meses y 18-23 meses respectivamente. Los niños cuyo control de crecimiento y desarrollo fue en el sector privado tuvieron menores probabilidades de ser vacunados para la primera dosis (OR: 0,30; IC95%: 0,21-0,43) y dosis de refuerzo (OR: 0,26; IC95%: 0,17-0,40) comparado con los que se controlaron en el sector público. Conclusiones . Según la ENDES 2017, Perú y ninguna de sus regiones alcanzó una cobertura del 95,0% para la primera dosis y su refuerzo. El control de crecimiento y desarrollo en establecimientos del sector público está asociado con la vacunación de sarampión en su primera dosis y refuerzo.


ABSTRACT Objectives . To estimate coverage and determine factors associated with measles vaccination in Peru. Materials and Methods . We conducted a secondary source study using the 2017 Demographic and Family Health Survey (ENDES). The reporting unit was a woman of childbearing age, 15 to 49 years; the unit of analysis was a child, 12 to 59 months (for the first dose), or a child, 18 to 59 months (for the booster dose) who had vaccination information. Coverage data were obtained from the vaccination card. Results . According to the vaccination card, coverage for the first dose was 70.2% (95% CI: 68.8-71.6); for the booster dose, 52% (95% CI: 50.5-53.6). Children aged 24-35 months were more likely to be vaccinated for the first dose (OR 1.59, 95% CI: 1.28-1.97) and booster dose (OR 2.04, 95% CI: 1.62-2.56), compared with children aged 12-23 months and 18-23 months respectively. Children with growth and development check-ups performed in the private sector were less likely to be vaccinated for the first dose (OR 0.30, 95% CI: 0.21-0.43) and booster dose (OR 0.26, 95% CI: 0.17-0.40), compared to those being monitored in the public sector. Conclusions . According to ENDES 2017, Peru and none of its regions achieved 95.0% coverage for the first and booster doses. Growth and development monitoring in public sector facilities is associated with measles vaccination in terms of first and booster doses.

18.
Rev Med Chil ; 147(5): 650-657, 2019 May.
Artículo en Español | MEDLINE | ID: mdl-31859898

RESUMEN

BACKGROUND: There is always a risk of importing infectious diseases when travelling abroad. AIM: To estimate the effective risk of a Chilean of acquiring measles during a travel by countries where measles outbreaks have been reported, considering the present level of immunity in the country. MATERIAL AND METHODS: Previously established mathematical models using differential equations were applied to calculate the risk of acquiring measles of people traveling to endemic areas. RESULTS: The probability of acquiring measles of a voyager is 8.11 x 10-8. CONCLUSIONS: These estimations help decision making about preventive measures for travelers to endemic measles areas.


Asunto(s)
Sarampión/transmisión , Modelos Teóricos , Medición de Riesgo/métodos , Enfermedad Relacionada con los Viajes , Chile/epidemiología , Brotes de Enfermedades , Humanos , Sarampión/epidemiología , Sarampión/prevención & control , Vacuna Antisarampión , Probabilidad , Factores de Riesgo , Factores de Tiempo , Vacunación
19.
J Pharm Pract ; : 897190019895437, 2019 Dec 26.
Artículo en Inglés | MEDLINE | ID: mdl-31875758

RESUMEN

Vaccine hesitancy has been identified as a top threat to global health by the World Health Organization. The current measles outbreak in the United States places even greater emphasis on the relevance of this topic. Vaccination is one of the most cost-effective methods to avoid preventable disease and associated complications. Safety concerns and lack of education commonly contribute to vaccination refusals. By providing patients evidence-based facts and education, pharmacists have the opportunity to address common misconceptions influencing the antivaccination movement and prevent future outbreaks of vaccine-preventable diseases.

20.
Acta Med Port ; 2019 Sep 12.
Artículo en Inglés | MEDLINE | ID: mdl-31851892

RESUMEN

Rubella is a vaccine preventable infection, and congenital rubella the most feared complication of this disease. Although young adult women are at greatest risk of post-vaccine rubella, this is also the group who potentially benefits the most from vaccine protection. Since post-vaccine disease has a mild and self-limited course, the benefit clearly exceeds the risk. During a measles outbreak in the north of Portugal, a 38-year-old woman presented with cervical posterior lymphadenopathies, fever and a maculo-papular rash one week after the administration of the measles, mumps and rubella vaccine. Measles was discarded and rubella viremia was demonstrated. Symptoms of rubella are non-specific and laboratory confirmation is essential. This is particularly relevant during a measles outbreak.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA